DNLI
Denali Therapeutics Inc

1,736
Mkt Cap
$2.52B
Volume
1.28M
52W High
$26.18
52W Low
$10.57
PE Ratio
-5.99
DNLI Fundamentals
Price
$17.44
Prev Close
$17.15
Open
$16.79
50D MA
$15.26
Beta
1.63
Avg. Volume
1.6M
EPS (Annual)
-$2.57
P/B
2.76
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Denali Therapeutics (NASDAQ:DNLI) Trading 8.8% Higher - Here's Why
Denali Therapeutics (NASDAQ:DNLI) Shares Up 8.8% - Here's What Happened...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
FY2028 Earnings Estimate for DNLI Issued By Leerink Partnrs
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report released on...
MarketBeat·3d ago
News Placeholder
FY2029 EPS Estimates for Denali Therapeutics Cut by Wedbush
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Wedbush reduced their FY2029 EPS estimates for shares of Denali Therapeutics in a research note issued to investors on Friday...
MarketBeat·5d ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Releases Earnings Results
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·6d ago
News Placeholder
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
Zacks·8d ago
News Placeholder
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Zacks·1mo ago
News Placeholder
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Zacks·3mo ago
News Placeholder
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Zacks·3mo ago
News Placeholder
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Zacks·4mo ago

Latest DNLI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.